 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kura Oncology reports inducement grants under Nasdaq listing rule

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the Company ) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Shares of Kura Oncology, Inc. (NASDAQ:KURA  Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $21.69, but opened at $21.25. Kura Oncology shares...

Kura Oncology (NASDAQ:KURA) Shares Gap Down to $21.69

Over the last three days, A.I.dvisor has detected that KURA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Kura Oncology (KURA, $21.94) Aroon Indicator entered an Uptrend on March 20, 2024.

Kura Oncology (KURA, $21.69) Aroon Indicator entered an Uptrend on March 19, 2024.

Kura Oncology (KURA, $21.04) Aroon Indicator entered an Uptrend on March 18, 2024.

Kura Oncology (KURA, $22.34) Aroon Indicator entered an Uptrend on March 15, 2024.

This is a Bearish indicator signaling KURA's price could decline from here. Traders may explore shorting the stock or put options...

Kura Oncology (KURA, $22) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 14, 2024

Kura Oncology (KURA, $22) Aroon Indicator entered an Uptrend on March 14, 2024.

Kura Oncology (KURA, $22.83) Aroon Indicator entered an Uptrend on March 13, 2024.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Volume (M)	660,270.00
52-Wk High	$24.17
52-Wk Low	$7.41

KURA Kura Oncology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals